- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02060474
Thyroid Hormone Analog Therapy in MCT8 Deficiency: Triac Trial Patients
Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial.
This therapeutical trial will be conducted in patients with the Allan-Herndon-Dudley Syndrome (AHDS), which is mutations in MCT8.
MCT8 is a thyroid hormone (TH) transporter which is crucial for the transport of TH from the blood into different tissues. Dysfunction of MCT8 results in a lack of TH (hypothyroidism) in tissues that depend on MCT8 for TH uptake. This local hypothyroidism in the brain of these patients causes severe psychomotor retardation.
In addition, TH serum parameters are highly abnormal in AHDS: high T3, low T4 and normal TSH levels. The high serum T3 levels cause local hyperthyroidism in tissues that do not depend on MCT8 for cellular transport of TH, resulting in a low body weight and reduced muscle mass.
Currently, no adequate treatment is available for the AHDS. A T3 analog that does not depend on MCT8 for its cellular entry could, at least partially, restore the abnormalities found in AHDS. Several in vivo, in vitro and animal studies have shown that the T3 analog Triac is a very promising candidate:
- Triac binds to the same TH receptors as T3;
- Cellular uptake of Triac does not depend on functional MCT8. Hence, in AHDS patients Triac will also be available in tissues that require functional MCT8 for TH uptake, e.g. the brain;
- In vitro studies have shown that neuronal cells differentiate equally well in the presence of either Triac or T3;
- In Mct8 deficient mice, Triac is taken up by the brain and suppresses serum TSH levels; consequently, serum T3 and T4 levels were lowered;
- Triac is the treatment of choice in patient with the resistance to thyroid hormone (RTH) syndrome. Patient with RTH have high serum TSH and thyroid hormone levels, which shows strong similarities to the profile found in AHDS patients; the longstanding experience with Triac in RTH indicates its safety and tolerability .
Thus, Triac treatment could result in normalization of the abnormal serum TH values in AHDS patients. Furthermore, Triac could replace the function of T3 in tissues that depend on MCT8 for TH uptake (e.g. brain).
The current trial will investigate if Triac treatment in ADHS patients
- reduces the toxic effects of the high T3 levels
- restores the local TH deficiency in brain.
Study Overview
Detailed Description
All patients were treated with Triac (Téatrois tablets 350 microgram, Rare Thyroid Therapeutics) by individualized dose-escalation, following a pre-defined dose-escalation protocol. After the initial dose of Triac (350 microgram) was administered and no predefined dose-limiting toxicities were observed, the daily dose was increased progressively in 350 microgram steps, with a goal of attaining serum total T3 concentrations within the target range of 1·4-2·5 nmol per liter. The maintenance Triac dose was continued throughout the rest of the study period, but could be further adjusted according to the dose-escalation protocol if T3 concentrations were outside the target range during control visits.
Patients were assessed for study outcomes at baseline and 12 months after starting Triac administration. In the interval, patients were evaluated and screened for clinical and biochemical signs of hypothyroidism or hyperthyroidism, adverse events were recorded and adherence to therapy was assessed. All study procedures were specified in standard operating procedures, and were performed by well-trained investigators. Neuropsychological tests were conducted according to their manual. All biochemical measurements were performed in a central laboratory (Erasmus Medical Centre). To account for any interference of Triac in the measurement of serum T3 concentrations, conventional methods were employed to correct for cross-reactivity.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
South-Holland
-
Rotterdam, South-Holland, Netherlands, 3000 CA
- Erasmus Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- clinically relevant mutation in the MCT8 gene, resulting in the clinical phenotype of AHDS.
Exclusion Criteria:
- Major illness or recent major surgery (within 4 weeks) unrelated to AHDS
- Patients who are participating in ongoing RCTs of therapeutic interventions (including clinical trials of investigational medicinal products);
- Known allergy to components in Triac tablets;
- Patients that have any contra-indication for Triac treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AHDS patients
all AHDS recruited for this study will be located in the experimental arm and will receive the investigational medicinal product Triac.
The Triac dose will be individually titrated to the optimal dose level.
|
Triac is a naturally occuring T3 metabolite with similar bioactivity and receptor binding profile.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
serum T3 concentrations
Time Frame: Participants will be evaluated with an expected average of 2 weeks during months 1-3 of the trial. During months 4-12, participants will be evaluated with an expected average of 6 weeks. For statistical analysis baseline and month 12 will be compared
|
Serum T3 concentrations will be determined to assess the effect of Triac
|
Participants will be evaluated with an expected average of 2 weeks during months 1-3 of the trial. During months 4-12, participants will be evaluated with an expected average of 6 weeks. For statistical analysis baseline and month 12 will be compared
|
serum free T4 concentrations
Time Frame: Participants will be evaluated with an expected average of 2 weeks during months 1-3 of the trial. During months 4-12 participants will be evaluated with an expected average of 6 weeks. For statistical analysis baseline and month 12 will be compared
|
Serum free T4 concentrations will be determined to assess the effect of Triac (co-primary end-point, supportive to changes in T3).
|
Participants will be evaluated with an expected average of 2 weeks during months 1-3 of the trial. During months 4-12 participants will be evaluated with an expected average of 6 weeks. For statistical analysis baseline and month 12 will be compared
|
serum TSH concentrations
Time Frame: Participants will be evaluated with an expected average of 2 weeks during months 1-3 of the trial. During months 4-12 participants will be evaluated with an expected average of 6 weeks. For statistical analysis baseline and month 12 will be compared
|
Serum TSH concentrations will be determined to assess the effect of Triac (co-primary end-point, supportive to changes in T3).
|
Participants will be evaluated with an expected average of 2 weeks during months 1-3 of the trial. During months 4-12 participants will be evaluated with an expected average of 6 weeks. For statistical analysis baseline and month 12 will be compared
|
serum total T4 concentrations
Time Frame: Participants will be evaluated with an expected average of 2 weeks during months 1-3 of the trial. During months 4-12 participants will be evaluated with an expected average of 6 weeks. For statistical analysis baseline and month 12 will be compared
|
Serum total T4 concentrations will be determined to assess the effect of Triac(co-primary end-point, supportive to changes in T3).
|
Participants will be evaluated with an expected average of 2 weeks during months 1-3 of the trial. During months 4-12 participants will be evaluated with an expected average of 6 weeks. For statistical analysis baseline and month 12 will be compared
|
serum reverse T3 concentrations
Time Frame: Participants will be evaluated with an expected average of 2 weeks during months 1-3 of the trial. During months 4-12 participants will be evaluated with an expected average of 6 weeks. For statistical analysis baseline and month 12 will be compared
|
Serum reverse T3 concentrations will be determined to assess the effect of Triac(co-primary end-point, supportive to changes in T3).
|
Participants will be evaluated with an expected average of 2 weeks during months 1-3 of the trial. During months 4-12 participants will be evaluated with an expected average of 6 weeks. For statistical analysis baseline and month 12 will be compared
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Heart rate
Time Frame: baseline and month 12 will be compared
|
Heart rate will be measures with an ECG and 24 h ambulatory monitoring
|
baseline and month 12 will be compared
|
serum sex-hormone binding globulin concentrations
Time Frame: baseline and month 12 will be compared
|
serum sex-hormone binding globulin concentrations will be measured as a proxi-parameter for tissue thyroid hormone status in the liver.
|
baseline and month 12 will be compared
|
Body weight
Time Frame: baseline and month 12 will be compared
|
Body weight will be measured in kg
|
baseline and month 12 will be compared
|
Blood pressure
Time Frame: baseline and month 12 will be compared
|
Blood pressure will be measured in mmHg
|
baseline and month 12 will be compared
|
serum total cholesterol concentrations
Time Frame: baseline and month 12 will be compared
|
serum total cholesterol concentrations will be measured as a proxi-parameter for tissue TH status in the liver.
|
baseline and month 12 will be compared
|
serum creatine kinase concentrations
Time Frame: baseline and month 12 will be compared
|
serum creatine kinase concentrations will be measured as a proxi-parameter for tissue TH status in the muscles.
|
baseline and month 12 will be compared
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Monitoring of adverse effects.
Time Frame: up to one year (= whole study period)
|
Family members and caregivers of the included patients will be asked to report all adverse effects to one of the investigators.
|
up to one year (= whole study period)
|
A routine trans-thoracic cardiac ultrasound
Time Frame: 12 months
|
the effects of Triac on the heart function will be measured using cardiac ultrasonography during the first visit (T0) and after 12 months (T12), reflecting the effect of Triac on the heart over a period of 1 year.
|
12 months
|
ECG
Time Frame: Participants will be evaluated with an expected average of 2 weeks during months 1-3 of the trial. During months 4-12 participants will be evaluated with an expected average of 6 weeks.
|
The effect of Triac on the heart rhythm will be assessed with an ECG
|
Participants will be evaluated with an expected average of 2 weeks during months 1-3 of the trial. During months 4-12 participants will be evaluated with an expected average of 6 weeks.
|
Bone Mineral Density (total body)
Time Frame: Bone mineral density will be measured during the first visit of the trial (T0) and after 12 months (T12) reflecting the effect of Triac over a 1 year period
|
Bone mineral density of total body will be measured by DXA scan
|
Bone mineral density will be measured during the first visit of the trial (T0) and after 12 months (T12) reflecting the effect of Triac over a 1 year period
|
Motor function, using the Gross Motor Function Measure
Time Frame: baseline and month 12 will be compared
|
motor function will be measured during the first visit of the trial (T0) and after 12 months (T12) reflecting the effect of Triac over a 1 year period
|
baseline and month 12 will be compared
|
Cognitive function using the Bayley Scales of Infant Development III
Time Frame: baseline and month 12 will be compared
|
cognitive function will be measured during the first visit of the trial (T0) and after 12 months (T12) reflecting the effect of Triac over a 1 year period
|
baseline and month 12 will be compared
|
Adaptive behavior by the Vineland adaptive behavior scale
Time Frame: baseline and month 12 will be compared
|
adaptive behavior will be measured during the first visit of the trial (T0) and after 12 months (T12) reflecting the effect of Triac over a 1 year period
|
baseline and month 12 will be compared
|
Bone Mineral Density of ultradistal ulna
Time Frame: Bone mineral density will be measured during the first visit of the trial (T0) and after 12 months (T12) reflecting the effect of Triac over a 1 year period
|
Bone mineral density of ultradistal ulna will be measured by DXA scan
|
Bone mineral density will be measured during the first visit of the trial (T0) and after 12 months (T12) reflecting the effect of Triac over a 1 year period
|
Bone Mineral Density of ultradistal radius
Time Frame: Bone mineral density will be measured during the first visit of the trial (T0) and after 12 months (T12) reflecting the effect of Triac over a 1 year period
|
Bone mineral density of ultradistal radius will be measured by DXA scan
|
Bone mineral density will be measured during the first visit of the trial (T0) and after 12 months (T12) reflecting the effect of Triac over a 1 year period
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: W.E. Visser, dr,, Erasmus Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- MCT8-2014-1
- 2014-000178-20 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allan-Herndon-Dudley Syndrome
-
Rare Thyroid Therapeutics International ABErasmus Medical CenterActive, not recruitingAllan-Herndon-Dudley SyndromeUnited States, Netherlands, Czechia, Germany
-
Kaplan Medical CenterWeizmann Institute of ScienceRecruitingMonocarboxylate Transporter 8 DeficiencyIsrael
-
Rare Thyroid Therapeutics International ABPremier Research Group plc; Egetis TherapeuticsRecruitingMonocarboxylate Transporter 8 Deficiency | Allan-Herndon-Dudley SyndromeUnited States, United Kingdom, Netherlands
-
Rare Thyroid Therapeutics International ABEgetis Therapeutics; AnovoRxAvailableMonocarboxylate Transporter 8 Deficiency | Allan-Herndon-Dudley SyndromeUnited States
-
Rare Thyroid Therapeutics International ABVitaccess LtdCompletedAllan-Herndon-Dudley Syndrome | Monocarboxylate Transporter 8 (MCT8) DeficiencyUnited Kingdom
-
dr. Laura C. G. de Graaff-HerderRecruitingDisorders of Sex Development | Congenital Adrenal Hyperplasia | Tuberous Sclerosis | Kallmann Syndrome | Prader-Willi Syndrome | Neurofibromatosis | Rett Syndrome | 22q11 Deletion Syndrome | Turner Syndrome | Noonan Syndrome | Allan-Herndon-Dudley Syndrome | Saethre-Chotzen Syndrome | Congenital Hypopituitarism | Cornelia... and other conditionsNetherlands
-
Children's Hospital of PhiladelphiaIllumina, Inc.Active, not recruitingMucopolysaccharidoses | Leukodystrophy | Adrenoleukodystrophy | Adrenomyeloneuropathy | X-linked Adrenoleukodystrophy | Gangliosidoses | Metachromatic Leukodystrophy | Krabbe Disease | Refsum Disease | Cadasil | Sjogren-Larsson Syndrome | Allan-Herndon-Dudley Syndrome | White Matter Disease | GM2 Gangliosidosis | Zellweger... and other conditionsUnited States
-
Children's Hospital of PhiladelphiaEli Lilly and Company; University of Pennsylvania; Takeda; National Institute of... and other collaboratorsRecruitingMucopolysaccharidoses | Leukoencephalopathies | Leukodystrophy | Adrenoleukodystrophy | Adrenomyeloneuropathy | X-linked Adrenoleukodystrophy | Gangliosidoses | Metachromatic Leukodystrophy | Krabbe Disease | Refsum Disease | Cadasil | Sjogren-Larsson Syndrome | Allan-Herndon-Dudley Syndrome | White Matter Disease | GM2... and other conditionsUnited States
Clinical Trials on Triac
-
Rare Thyroid Therapeutics International ABErasmus Medical CenterActive, not recruitingAllan-Herndon-Dudley SyndromeUnited States, Netherlands, Czechia, Germany
-
Trophea Development ABUppsala UniversityUnknown